3/19/2013

Dr. Greg Geba announced he will resign as director of the FDA's Office of Generic Drugs, just as the FDA has started collecting generic-drug manufacturer user fees. A planned reorganization of the office played a role in his decision, Geba said in a memo. Dr. Janet Woodcock, director of the Center for Drug Evaluation & Research, will temporarily cover Geba's duties.

Full Story:
Pharmalot

Related Summaries